NanoViricides Share Price Today

NanoViricides NV-387 passes juvenile safety study for pediatric trials

NV-387 showed no adverse effects in juvenile mice at 1,230 mg/kg per dose. Study paves way for pediatric cohorts in Ebola and Mpox Phase III trials. Company faces substantial doubt about going concern status in FY26 report. Potential $200 million value from Priority Review Voucher if measles trial succeeds.

NanoViricides to present at NIBA investment conference in Florida

NanoViricides will present at NIBA's 153rd Investment Conference on October 7, 2026. Lead drug NV-387 entered Phase II trials for Ebola and Mpox in September 2026. FDA granted Orphan Drug Designation for NV-387 for Measles treatment. Potential Priority Review Voucher value estimated at $200-250 million.

NanoViricides details Phase II Ebola trial as DRC outbreak hits 4,018 deaths

Death toll from Bundibugyo Ebolavirus in DRC rises to 4,018 with 8,300 confirmed cases. Phase IIA trial for NV-387 Oral Gummies began enrollment on September 23, 2026. Nord Kivu province accounts for 40% of national confirmed cases despite limited treatment capacity. Crude case fatality rate stands at 48%, while infection-to-fatality rate is estimated at 67%. NV-387 offers oral delivery advantage over infusion-based competitors like MBP134 and Remdesivir.

NanoViricides starts Phase II trial of NV-387 for Ebola in DRC

NanoViricides started Phase II trial of oral NV-387 for Ebola in DRC on September 23, 2026. DRC outbreak reached 7,890 confirmed cases and 3,799 deaths as of September 23, 2026. Crude case fatality rate stands at 48%, with estimated probability of death at 67%. NV-387 is the only oral antiviral in trials, contrasting with IV-only PARTNERS trial drugs.

NanoViricides secures DRC approval for Phase II Ebola trial of NV-387

NanoViricides Inc secured ACOREP approval for a Phase II trial of NV-387 oral gummies against Bundibugyo Ebola in DRC. First dosing is expected within weeks using existing stock. The outbreak has grown 20% in one week to 4,945 cases with a 46% fatality rate, outpacing containment efforts.

NanoViricides seeks DRC approval for Ebola drug trial

NanoViricides has applied to ACOREP in the DRC for a Phase II trial of NV-387 Oral Gummies to treat the Bundibugyo Ebolavirus, amidst an outbreak that has caused over 930 deaths. The company has partnered with Om Sai Clinical Research Private Limited to lead the trial, leveraging existing drug stock already shipped to the region. NV-387 offers a scalable oral alternative to infusion-based therapies, which are currently being tested but face logistical challenges.